Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21


Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.

Ilcus C, Bagacean C, Tempescul A, Popescu C, Parvu A, Cenariu M, Bocsan C, Zdrenghea M.

Onco Targets Ther. 2017 Apr 28;10:2349-2363. doi: 10.2147/OTT.S133385. eCollection 2017. Review.


Checkpoint inhibitors in hematological malignancies.

Ok CY, Young KH.

J Hematol Oncol. 2017 May 8;10(1):103. doi: 10.1186/s13045-017-0474-3. Review.


Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, Lin Y, Asmus E, Nowakowski GS, Conte MJ, Bowen DA, Aitken CN, Van Dyke DL, Greipp PT, Liu X, Wu X, Zhang H, Secreto CR, Tian S, Braggio E, Wellik LE, Micallef I, Viswanatha DS, Yan H, Chanan-Khan AA, Kay NE, Dong H, Ansell SM.

Blood. 2017 Jun 29;129(26):3419-3427. doi: 10.1182/blood-2017-02-765685. Epub 2017 Apr 19.


Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.

Gravelle P, Burroni B, Péricart S, Rossi C, Bezombes C, Tosolini M, Damotte D, Brousset P, Fournié JJ, Laurent C.

Oncotarget. 2017 Jul 4;8(27):44960-44975. doi: 10.18632/oncotarget.16680. Review.


PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment.

Flies AS, Lyons AB, Corcoran LM, Papenfuss AT, Murphy JM, Knowles GW, Woods GM, Hayball JD.

Front Immunol. 2016 Dec 9;7:581. doi: 10.3389/fimmu.2016.00581. eCollection 2016.


Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas.

Tosolini M, Algans C, Pont F, Ycart B, Fournié JJ.

Oncoimmunology. 2016 May 19;5(7):e1188246. doi: 10.1080/2162402X.2016.1188246. eCollection 2016 Jul.


PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.

Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA, Chen BJ.

Oncotarget. 2016 Sep 13;7(37):59976-59986. doi: 10.18632/oncotarget.11045.


Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology.

Loghavi S, Wang SA, Medeiros LJ, Jorgensen JL, Li X, Xu-Monette ZY, Miranda RN, Young KH.

Leuk Lymphoma. 2016 Dec;57(12):2804-2812. Epub 2016 Apr 22.


Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functions.

Germain C, Guillaudeux T, Galsgaard ED, Hervouet C, Tekaya N, Gallouet AS, Fassy J, Bihl F, Poupon G, Lazzari A, Spee P, Anjuère F, Pangault C, Tarte K, Tas P, Xerri L, Braud VM.

Oncoimmunology. 2015 Apr 8;4(8):e1026503. eCollection 2015 Aug.


Anti-programmed cell death protein-1/ligand-1 therapy in different cancers.

Homet Moreno B, Ribas A.

Br J Cancer. 2015 Apr 28;112(9):1421-7. doi: 10.1038/bjc.2015.124. Epub 2015 Apr 9. Review.


Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.

Reiss KA, Forde PM, Brahmer JR.

Immunotherapy. 2014;6(4):459-75. doi: 10.2217/imt.14.9. Review.


At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.

Callahan MK, Wolchok JD.

J Leukoc Biol. 2013 Jul;94(1):41-53. doi: 10.1189/jlb.1212631. Epub 2013 May 10. Review.


The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.

Brusa D, Serra S, Coscia M, Rossi D, D'Arena G, Laurenti L, Jaksic O, Fedele G, Inghirami G, Gaidano G, Malavasi F, Deaglio S.

Haematologica. 2013 Jun;98(6):953-63. doi: 10.3324/haematol.2012.077537. Epub 2013 Jan 8.


The role of B7 family molecules in hematologic malignancy.

Greaves P, Gribben JG.

Blood. 2013 Jan 31;121(5):734-44. doi: 10.1182/blood-2012-10-385591. Epub 2012 Dec 6. Review.


Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia.

Grzywnowicz M, Zaleska J, Mertens D, Tomczak W, Wlasiuk P, Kosior K, Piechnik A, Bojarska-Junak A, Dmoszynska A, Giannopoulos K.

PLoS One. 2012;7(4):e35178. doi: 10.1371/journal.pone.0035178. Epub 2012 Apr 19.


Follicular helper T cells: implications in neoplastic hematopathology.

Gaulard P, de Leval L.

Semin Diagn Pathol. 2011 Aug;28(3):202-13. Review.


Gene Expression Profiling for In Silico Microdissection of Hodgkin's Lymphoma Microenvironment and Identification of Prognostic Features.

Bertucci F, Chetaille B, Xerri L.

Adv Hematol. 2011;2011:485310. doi: 10.1155/2011/485310. Epub 2010 Dec 13.


In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors.

Berthon C, Driss V, Liu J, Kuranda K, Leleu X, Jouy N, Hetuin D, Quesnel B.

Cancer Immunol Immunother. 2010 Dec;59(12):1839-49. doi: 10.1007/s00262-010-0909-y. Epub 2010 Sep 4.


The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation.

Marafioti T, Paterson JC, Ballabio E, Chott A, Natkunam Y, Rodriguez-Justo M, Plonquet A, Rodriguez-Pinilla SM, Klapper W, Hansmann ML, Pileri SA, Isaacson PG, Stein H, Piris MA, Mason DY, Gaulard P.

Haematologica. 2010 Mar;95(3):432-9. doi: 10.3324/haematol.2009.010991.

Supplemental Content

Support Center